RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

OT: Prana
The MF story has the dates wrong. The Huntington's trial results (109 patients) are due in October, the AD trial--only 40 patients, so a minimal size n--by the end of March. Prana recently accepted my invitation to participate in a conference whose neuro component I organize, and I wouldn't have invited them if I didn't think they have a shot at making it work. The previous Phase II was pretty skimpy, and they had to dig to find some evidence of positive effect, but Tanzi/Bush are very respected people in the field, the theory does have some interface with both amyloid and tau,,so it's not completely tangential to the main ideologies.

The two trials together--since it is the same drug, and the premise is that it addresses the same metal-binding pathology downstream in both disorders--are probably the most important datapoints for AD that we will see in the next 12+ months.

This does not represent a prediction they will succeed, but they have a chance.

NP